AB0622 Significance of body mass index for the effect of bisphosphonate therapy in women with postmenopausal osteoporosis

• Published in: Annals of the rheumatic diseases Vol. 72; no. Suppl 3; pp. A979 - A980
• Main Authors: Milenkovic, S. B., Dimic, A. N., Aleksic, I. M., Dimic, N. A., Stojanovic, S., Stamenkovic, B.
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd and European League Against Rheumatism 01.06.2013; BMJ Publishing Group LTD
• ISSN: 0003-4967; 1468-2060
• DOI: 10.1136/annrheumdis-2013-eular.2944

Background Osteoporosis is generalized bone disease characterized by disturbed bone strength, consequently fracture predisposition increases. One of the risk factors for osteoporotic fractures is the Body Mass Index (BMI) and it is evaluated according to the following criteria: malnutrition- to 18 kg/m2, normal body weight - 20-25 kg/m2, overweight - 25-30 kg/m2 and obesity - over 30 kg/m2. Objectives To determine the significance of Body Mass Index for the effect of bisphosphonate therapy in women with newly diagnosed postmenopausal osteoporosis Methods 92 women, with newly diagnosed postmenopausal osteoporosis, were included in this research. According to BMI values, the patients were divided into groups of under 18, 18 to 25, 25 to 30 and over 30 kg/m2. The groups were homogenous in relation to other risk factors for the appearance of osteoporosis. Bone mineral density (BMD) was measured with dual energy X-ray absorptiometry (DXA) on the Hologic Discovery machine before the therapy, as well as, 12 months after the bisphosphonate therapy. Results T-score values and BMD during 12 month therapy with bisphosphonate the most increased in examinees whose BMI values were in the range of 25 to 30 kg/m2 (0,330±0,275), and the least in women with BMI below 18 (0,190±0,223), but ANOVA and Dante’s test did not confirm the existence of significant differences between all compared groups. Conclusions Statistically significant difference in the effect of the bisphosphonate therapy was not found in postmenopausal women with newly diagnosed osteoporosis nor with different body mass index. References Kanis JA. Diagnosis of osteoporosis and assessmentof fracture risk. Lancet 2002;359:1929-1936 Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Oden A. Assessment of fracture risk. Osteoporosis Int 2005;16(6):581-589 S. Ilić. Poremećaji ishrane. Interna medicina 2004;2:386-389 Epstein S. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther. 2006; 28(2):151-173 Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatolog 2005;17(4):462-466 Asche S, Nelson R, McAdam-Marx C, Jhaveri M and Ye X. Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA. Osteoporosis international 2009; 1427-1436, 2009 Asomaning K, Bertone-Johnson E, Nasca P, Hooven F, Pekow P. Women with low BMI are at increased risk of osteoporosis. Journal of Women’s Health 2006; 15(9): 1028-1034 De Laet C, Kanis JA, Oden E, Johanson E. Body mass index as a predictor of fracture risk: A meta-analysis. International Osteoporosis Foundation and National Osteoporosis Foundation 2005 Ravn P, Cizza G, Bjarnason NH. Low Body Mass Index Is an Important Risk Factor for Low Bone Mass and Increased Bone Loss in Early Postmenopausal Women. Journal of Bone and Mineral Research 1999;14(9):1622–1627 Disclosure of Interest None Declared